BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

RuiYi (formerly Anaphore) 

10931 North Torrey Pines Road
Suite 101
La Jolla  California  92037  U.S.A.
Phone: 858-587-4815 Fax: 858-587-4854


SEARCH JOBS




Industry
Biotechnology

Segment
Biotechnology





 Company News
RuiYi (formerly Anaphore) Closes $4 Million Venture Loan From Silicon Valley Bank 6/11/2014 9:49:39 AM
RuiYi (formerly Anaphore) And iHuman Institute Form Collaboration To Identify Novel Antibodies Targeting GPCRs 6/11/2014 9:45:48 AM
Week in Review: RuiYi (formerly Anaphore) Raises $15 Million For mAb Development 3/30/2014 3:04:48 PM
San Diego's RuiYi (formerly Anaphore) Grabs $15 Million For Monoclonal Antibody Research 3/27/2014 7:03:58 AM
Week in Review: RuiYi (formerly Anaphore) Signs Up Shanghai's Genor to Develop mAb in China 5/20/2013 9:24:09 AM
RuiYi (formerly Anaphore) and Genor BioPharma Collaborate on Development in China of RYI-008, a Novel Therapeutic for Autoimmune Diseases and Cancer 5/16/2013 10:08:27 AM
CMC Biologics and RuiYi (formerly Anaphore) Enter into an Agreement for Development of a Novel Anti-IL-6 Monoclonal Antibody 5/14/2013 9:28:56 AM
Anaphore Announces Name Change to RuiYi (formerly Anaphore) and New Additions to Shanghai Management Team 10/4/2012 6:45:47 AM
Anaphore, Inc. Announces Acquisition of RuiYi in Shanghai China for GPCR Biologics Drug Discovery Platform 3/22/2012 10:07:32 AM
Anaphore, Inc. Appoints Paul A. Grayson President and CEO 6/20/2011 6:55:37 AM
12